Em pacientes com fibrilação atrial, os desfechos de 4 anos do estudo randomizado PRAGUE-17 mostraram que o fechamento do apêndice atrial esquerdo foi não inferior a anticoagulação oral para prevenir eventos isquêmicos e hemorrágicos.

Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17 – Journal of the American College of Cardiology (link para o resumo – $ para o texto completo)

Comentários:

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term – TCTMD

PRAGUE-17: LAAC Noninferior to NOACs For Major AFib-Related CV, Neurological Events Longer-Term – American College of Cardiology

Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-Risk Atrial Fibrillation Patients – PRAGUE-17 – American College of Cardiology

Comentário no Twitter

📌 The PRAGUE-17 trial showed that left atrial appendage occlusion was noninferior to a #NOAC at preventing net ischemic & bleeding events. Check out ACC’s Visual Abstract from #TCT2021 to learn more here: https://t.co/NTVc4wpH6W pic.twitter.com/9EBWRvs72O

— American College of Cardiology (@ACCinTouch) November 6, 2021